Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7 808 patients in France
- PMID: 33016546
- DOI: 10.1111/apt.16040
Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7 808 patients in France
Comment in
-
Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7808 patients in France. Authors' reply.Aliment Pharmacol Ther. 2020 Oct;52(7):1249-1250. doi: 10.1111/apt.16055. Aliment Pharmacol Ther. 2020. PMID: 33016549 No abstract available.
Comment on
-
2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases.Aliment Pharmacol Ther. 2020 Jul;52(2):276-283. doi: 10.1111/apt.15804. Epub 2020 Jun 7. Aliment Pharmacol Ther. 2020. PMID: 32359205 Free PMC article.
References
REFERENCES
-
- Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020;52:276-283.
-
- Li X, Andersen KM, Chang H-Y, Curtis JR, Alexander GC. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2020;79:285-291.
-
- Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155:337-346.e10.
-
- Brat GA, Weber GM, Gehlenborg N, et al. International electronic health record-derived COVID-19 clinical course profiles: the 4CE Consortium. Infectious Diseases (except HIV/AIDS). 2020. https://doi.org/10.1101/2020.04.13.20059691
-
- Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic testing for severe acute respiratory syndrome-related coronavirus-2: a narrative review. Ann Intern Med. 2020;172:726-734.